Citations

Clear

3942 citation(s) found for "To, Van".

Effects of exercise during chemotherapy for breast cancer on long-term cardiovascular toxicity
Naaktgeboren, Willeke R. , Stuiver, Martijn M. , Harten, Wim H. van , Wall, Elsken van der , Velthuis, Miranda J. , Groen, Wim G , Aaronson, Neil K. , Scott, Jessica M. , Sonke, Gabe S. , Leiner, Tim , Teske, Arco J. , May, Anne M.

Mayo Clinic

Open Heart | October 30, 2023 | Volume: 10 | Issue: 2 | Pages: e002464

10.1136/openhrt-2023-002464 | PMID 37903570 Get It

Objective Animal data suggest that exercise during chemotherapy is cardioprotective, but clinical evidence to support this is limited. This study evaluated the effect of exercise during chemotherapy for breast cancer on long-term cardiovascular toxicity. Methods This is a follow-up study of two previously performed randomised trials in patients with breast cancer allocated to exercise during chemotherapy or non-exercise controls. Cardiac imaging parameters, including T1 mapping (native T1, extracellular volume fraction (ECV)), left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS), cardiorespiratory fitness, and physical activity levels, were acquired 8.5 years post-treatment. Results In total, 185 breast cancer survivors were included (mean age 58.9±7.8 years), of whom 99% and 18% were treated with anthracyclines and trastuzumab, respectively. ECV and Native T1 were 25.3%±2.5% and 1026±51 ms in the control group, and 24.6%±2.8% and 1007±44 ms in the exercise group, respectively. LVEF was borderline normal in both groups, with an LVEF<50% prevalence of 22.5% (n=40/178) in all participants. Compared with control, native T1 was statistically significantly lower in the exercise group (β=−20.16, 95% CI −35.35 to −4.97). We found no effect of exercise on ECV (β=−0.69, 95% CI −1.62 to 0.25), LVEF (β=−1.36, 95% CI −3.45 to 0.73) or GLS (β=0.31, 95% CI −0.76 to 1.37). Higher self-reported physical activity levels during chemotherapy were significantly associated with better native T1 and ECV. Conclusions In long-term breast cancer survivors, exercise and being more physically active during chemotherapy were associated with better structural but not functional cardiac parameters. The high prevalence of cardiac dysfunction calls for additional research on cardioprotective measures, including alternative exercise regimens. Trial registration number NTR7247.
Solitary Fibrous Tumor of Breast and Axilla: Clinicopathological Profile of Five Tumors With Comparison of Risk Stratification Models
Hoda, Raza S. , Duckworth, Lauren A. , Gilmore, Hannah , Cui, Xiaoyan , Arnam, John S. Van , Zhang, Gloria, Rowe, J. Jordi, Xiao, Huijun , Azzato, Elizabeth M. , Goldblum, John R. , Fritchie, Karen , Downs, Erinn, Fritchie, Karen J , Downs, Erinn P, Hoda, Raza S , McIntire, Patrick J. , Sciallis, Andrew P. , Xiao, Huijun

Mayo Clinic

International Journal of Surgical Pathology | October 30, 2023 | Volume: 32 | Issue: 5 | Pages: 895-907

10.1177/10668969231204957 | PMID 37899729 Get It

Introduction: Solitary fibrous tumor (SFT) is a fibroblastic tumor with malignant potential that is underpinned by a recurrent inv12(q13q13)-derived NAB2::STAT6 fusion. Breast and axilla are uncommon locations for this entity. Methods: Records of two academic institutions were electronically searched for breast and axillary SFTs. Clinical and pathologic data were reviewed. Literature review for breast or axillary SFTs was performed. Present study and previously reported tumors were stratified using five SFT risk models: original and modified Demicco metastatic risk, Salas local recurrence risk, Salas metastatic risk, and Thompson local recurrence risk. Results: Five patients with breast or axillary SFT were identified. Median age was 49 years, and median follow-up (available for four patients) was 82 months. Three patients showed no evidence of disease, and one developed recurrence. Literature review identified 58 patients with breast or axillary SFT. Median age was 54 years, and median follow-up (available for 35 patients) was 24 months. Thirty-one patients showed no evidence of disease, three developed recurrence, and one developed metastasis. Original and modified Demicco models and Thompson model showed the highest sensitivity; original and modified Demicco models and Salas metastatic risk model demonstrated the highest specificity. Kaplan–Meier models were used to assess recurrence-free probability (RFP). Original and modified Demicco models predicted RFP when stratified by “low risk” and “moderate/intermediate and high risk” tumor, though sample size was small. Conclusions: While many SFTs of breast and axilla remain indolent, a subset may develop recurrence and rarely metastasize. The modified Demicco risk model demonstrated optimal performance characteristics.
Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Bergeman, Auke T. , Lieve, Krystien V.V. , Kallas, Dania , Bos, J. Martijn , Noguer, Ferran Rosés i, Denjoy, Isabelle , Zorio, Esther , Kammeraad, Janneke A.E. , Peltenburg, Puck J. , Tobert, Katie, Aiba, Takeshi , Batra, Anjan S. , Borggrefe, Martin , Cox, Moniek G.P.J. , Dhillon, Santokh , Etheridge, Susan P. , Fischbach, Peter , Franciosi, Sonia , Horie, Minoru , Johnsrude, Christopher L. , Kane, Austin, Krause, Ulrich , Kwok, Sit‐Yee , Ohno, Seiko , Roberts, Jason D. , Robyns, Tomas , Sacher, Frédéric , Semsarian, Christopher , Swan, Heikki, Tavačová, Terézia , Tisma‐Dupanovic, Svjetlana , Tfelt‐Hansen, Jacob , Yap, Sing‐Chien , Till, Janice, Sanatani, Shubhayan , Ackerman, Michael J. , Wilde, Arthur A.M. , Rosés‐Noguer, Ferran , Atallah, Joseph , Drago, Fabrizio , Brugada, Ramón , Borggrefe, Martin , Clur, Sally-Ann B , Cox, Moniek G P J , Davis, Andrew , Dhillon, Santokh , Etheridge, Susan P , Haugaa, Kristina , Horie, Minoru , Johnsrude, Christopher , Krause, Ulrich , LaPage, Martin J , Ohno, Seiko , Probst, Vincent , Roberts, Jason D , Robyns, Tomas , Sacher, Frederic , Semsarian, Christopher , Skinner, Jonathan R , Tavacova, Terezia , Tisma-Dupanovic, Svjetlana , Tfelt-Hansen, Jacob , Yap, Sing-Chien , Kannankeril, Prince J , Leenhardt, Antoine , Sanatani, Shubhayan , Ackerman, Michael J , Wilde, Arthur A M , van der Werf, Christian , Bos, Johan M , Zorio, Esther , Denjoy, Isabelle , Rosés-Noguer, Ferran , Kammeraad, Janneke A E , Lieve, Krystien V , Peltenburg, Puck J , Aiba, Takeshi , Atallah, Joseph , Clur, Sally‐Ann B. , Davis, Andrew M. , Haugaa, Kristina H. , Skinner, Jonathan R. , Kannankeril, Prince J. , Leenhardt, Antoine , Tanck, Michael , Werf, Christian van der , Bergeman, Auke T

Mayo Clinic

Circulation | October 27, 2023 | Volume: 148 | Issue: 25 | Pages: 2029-2037

10.1161/circulationaha.123.064786 | PMID 37886885 Get It

BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14–29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7–3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4–7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0–6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38–0.83]; P =0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31–0.77]; P =0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14–0.45]; P <0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.
Timing of Ureteral Stent Removal After Ureteroscopy on Stent-Related Symptoms: A Validated Questionnaire Comparison of 3 and 7 Days Stent Duration
Heidenberg, Daniel , Nauheim, Jennifer, Grant, Campbell , Mi, Lanyu , Walt, Charles Van Der , Mufarrij, Patrick, Heidenberg, Daniel J, Van der Walt, Charles

Mayo Clinic

Journal of Endourology | October 27, 2023 | Volume: 38 | Issue: 1 | Pages: 82-87

10.1089/end.2023.0189 | PMID 37885220 Get It

Optimizing schools of cytology: Discussions from the 2022 ASC/IAC Cytology Education Symposium, North American Strategies, and European Symbiosis
LeBlanc, Jenna B., Smith, Michele A., McNair, Sean A., Hansing, Kara L. , Bammert, Catherine E., Russell, Donna , Howell, Joshua M. , Alperstein, Susan, Lennen, Kelly, Paradis, Veronika Anic, Zuylen‐Manders, Lia van, Liikanen, Eeva , Freund, Gregory G. , Davey, Diane D. , Goulart, Robert A. , Yuil‐Valdes, Ana, Brainard, Jennifer , Hitchens, Sandra W., Donnelly, Amber , Srebotnik-Kirbis, Irena , Sturgis, Charles D. , Vielh, Philippe R.

Mayo Clinic

Cytopathology | October 25, 2023 | Volume: 35 | Issue: 1 | Pages: 2-6

10.1111/cyt.13314 | PMID 37877689 Get It

AbstractThis report highlights information and outcomes from the November 2022 ASC/IAC joint Cytology Education Symposium, an annual conference organized by the Cytology Programs Review Committee. The manuscript provides information on shared educational opportunities and practices for cytology students and other learners in anatomic pathology, discusses recruitment strategies for schools of cytology, conveys teaching resources, introduces perspectives on virtual microscopy and online learning, and transmits information about wellness of students in schools of cytology.
Comparing Speech Recognition Outcomes Between Cochlear Implants and Auditory Brainstem Implants in Patients With NF2-Related Schwannomatosis
Dornhoffer, James R. , Plitt, Aaron , Lohse, Christine M. , Driscoll, Colin L. W., Neff, Brian A., Saoji, Aniket A. , Link, Michael J. , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | October 24, 2023 | Volume: 45 | Issue: 1 | Pages: 29-35

10.1097/mao.0000000000004047 | PMID 37875011 Get It

Objective To compare cochlear implant (CI) and auditory brainstem implant (ABI) performance in patients with NF2-related schwannomatosis (NF2) Study Design Historical cohort. Setting Tertiary academic center. Patients A total of 58 devices among 48 patients were studied, including 27 ABIs implanted from 1997 to 2022 and 31 CIs implanted from 2003 to 2022. Three patients had bilateral ABIs, three had bilateral CIs, three had an ABI on one side and a CI on the other, one had a CI that was later replaced with an ipsilateral ABI, and one had an ABI and CI concurrently on the same side. Interventions CI or ABI ipsilateral to vestibular schwannoma. Main Outcome Measures Open-set speech perception, consonant-nucleus-consonant word scores, and AzBio sentence in quiet scores. Results Among all patients, 27 (47%) achieved open-set speech perception, with 35 (61%) daily users at a median of 24 months (interquartile range [IQR], 12–87 mo) after implantation. Comparing outcomes, CIs significantly outperformed ABIs; 24 (77%) CIs achieved open-set speech perception compared with 3 (12%) ABIs, with median consonant-nucleus-consonant and AzBio scores of 31% (IQR, 0–52%) and 57% (IQR, 5–83%), respectively, for CIs, compared with 0% (IQR, 0–0%) and 0% (IQR, 0–0%), respectively, for ABIs. Patients with ABIs were younger at diagnosis and at implantation, had larger tumors, and were more likely to have postoperative facial paresis. Conclusion Many patients with NF2-associated vestibular schwannoma achieved auditory benefit with either a CI or an ABI; however, outcomes were significantly better in those patients who were able to receive a CI. When disease and anatomy permit, hearing rehabilitation with a CI should be considered over an ABI in these patients. Tumor management strategies that increase the ability to successfully use CIs should be strongly considered given the high risk of losing bilateral functional acoustic hearing in this population.
Rationale for the Development of a Novel Clinical Grading Scale for Postoperative Facial Nerve Function: Results of a Multidisciplinary International Working Group
Carlson, Matthew L. , Lohse, Christine M. , Babu, Seilesh C. , Barker, Frederick G., Barnett, Samuel , Biggs, Nigel, Boahene, Kofi , Breen, Joseph T. , Brown, Kevin D. , Cayé‐Thomasen, Per , Cosetti, Maura K. , Deep, Nicholas L. , Dornhoffer, James R. , Forner, David , Hansen, Marlan R. , Kalamarides, Michel , Kim, Irene A., Kircher, Matthew L., Link, Michael J., Lloyd, Simon , Lund‐Johansen, Morten , Marinelli, John P. , Matthies, Cordula , Moore, Eric J. , Nassiri, Ashley M. , Neff, Brian A., Patel, Neil S. , Celda, María Peris, Plitt, Aaron , Sweeney, Alex D. , Tasche, Kendall K. , Tatagiba, Marcos , Tveiten, Øystein Vesterli , Vrabec, Jeffrey T. , Wanna, George B. , Weisskopf, Peter A., Tatagiba, Marcos , Agazzi, Siviero , Bi, Wenya Linda , Dey, Jacob K. , Gurgel, Richard Klaus , Hunter, Jacob B. , King, Andrew Thomas , Lassaletta, Luis , Mehta, Vikas , Nelson, Rick F , Olson, Jeffrey J. , Price, Daniel L. , Roland, J. Thomas , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | October 24, 2023 | Volume: 44 | Issue: 10 | Pages: e747-e754

10.1097/mao.0000000000004039 | PMID 37875014 Get It

Objective The objective of the current study was to present the results of an international working group survey identifying perceived limitations of existing facial nerve grading scales to inform the development of a novel grading scale for assessing early postoperative facial paralysis that incorporates regional scoring and is anchored in recovery prognosis and risk of associated complications. Study Design Survey. Setting A working group of 48 multidisciplinary clinicians with expertise in skull base, cerebellopontine angle, temporal bone, or parotid gland surgery. Results House-Brackmann grade is the most widely used system to assess facial nerve function among working group members (81%), although more than half (54%) agreed that the system they currently use does not adequately estimate the risk of associated complications, such as corneal injury, and confidence in interrater and intrarater reliability is generally low. Simplicity was ranked as the most important attribute of a novel postoperative facial nerve grading system to increase the likelihood of adoption, followed by reliability and accuracy. There was widespread consensus (91%) that the eye is the most critical facial region to focus on in the early postoperative setting. Conclusions Members were invited to submit proposed grading systems in alignment with the objectives of the working group for subsequent validation. From these data, we plan to develop a simple, clinically anchored, and reproducible staging system with regional scoring for assessing early postoperative facial nerve function after surgery of the skull base, cerebellopontine angle, temporal bone, or parotid gland.
A 7-Year-Old Boy with Fever and Dark Urine
Chuang, Tony M. , Bu, Lihong , Opp, Derek N., Potretzke, Theodora A. , Dorn, Charlotte S. Van , Tran, Cheryl L. , Van Dorn, Charlotte S, Huskins, W. Charles , Dearani, Joseph A. , Hanna, Christian

Mayo Clinic

NEJM Evidence | October 24, 2023 | Volume: 2 | Issue: 11 | Pages: No page available

10.1056/evidmr2300191 | PMID 38320528 Get It

Lower Cranial Nerve Schwannomas: Cohort Study and Systematic Review
Carlstrom, Lucas P. , Oushy, Soliman , Perry, Avital , Brown, Paul D. , Peris‐Celda, Maria , Graffeo, Christopher S. , Link, Michael J., Oushy, Soliman H , Bauman, Megan M. J. , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Neurosurgery | October 24, 2023 | Volume: 94 | Issue: 4 | Pages: 745-755

10.1227/neu.0000000000002735 | PMID 37874134 Get It

BACKGROUND AND OBJECTIVES: Schwannomas originating from the lower cranial nerves (LCNS) are rare and pose a significant surgical challenge. Resection is the mainstay treatment; however, risk of treatment morbidity is considerable, and the available literature regarding differential treatment outcomes in this vulnerable population is sparse. METHODS: A single-institution cohort study and systematic literature review of LCNS were performed. RESULTS: Fifty-eight patients were included: 34 underwent surgical resection and 24 underwent stereotactic radiosurgery (SRS). The median age at diagnosis was 48 years (range 17-74). Presenting symptoms were dysphagia (63%), dysarthria/hypophonia (47%), imbalance (33%), and hearing loss/tinnitus (30%). Tumor size was associated with surgical resection, as compared with initial SRS (4.1 cm vs 1.5 cm, P = .0001). Gross total resection was obtained in 52%, with tumor remnants predominantly localized to the jugular foramen (62%). Post-treatment worsening of symptoms occurred in 68% of surgical and 29% of SRS patients ( P = .003). Postoperative symptoms were mostly commonly hypophonia/hoarseness (63%) and dysphagia (59%). Seven patients (29%) had new neurological issues after SRS treatment, but symptoms were overall milder. The median follow-up was 60 months (range 12-252); 98% demonstrated meaningful clinical improvement. Eighteen surgical patients (53%) underwent adjuvant radiation at a median of 5 months after resection (range 2-32). At follow-up, tumor control was 97% in the surgical cohort and 96% among SRS patients. CONCLUSION: Although LCNS resection is potentially morbid, most postoperative deficits are transient, and patients achieve excellent tumor control—particularly when paired with adjuvant SRS. For minimally symptomatic patients undergoing surgical intervention, we advise maximally safe resection with intracapsular dissection to preserve nerve integrity where possible. For residual or as a primary treatment modality, SRS is associated with low morbidity and high rates of long-term tumor control.
Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial
Yamada, Satsuki , Bartúnek, Jozef , Povsic, Thomas J. , Davison, Beth A. , Edwards, Christopher , Behfar, Atta , Metra, Marco , Filippatos, Gerasimos , Vanderheyden, Marc , Cotter, Gad , Davison, Beth A , Behfar, Atta , Metra, Marco , Filippatos, Gerasimos S , Vanderheyden, Marc , Wijns, William , Terzic, Andre , Bartunek, Jozef , Wijns, William , Terzic, André

Mayo Clinic

Stem Cells Translational Medicine | October 24, 2023 | Volume: 13 | Issue: 2 | Pages: 116-124

10.1093/stcltm/szad078 | PMID 38006196 Get It

Abstract Patients with heart failure experience limitations in daily activity and poor quality-of-life. Prospective surveillance of health-related quality-of-life supplemented traditional death and hospitalization outcomes in the multinational, randomized, double-blinded CHART-1 clinical trial that assessed cardiopoiesis-guided cell therapy in ischemic heart failure patients with reduced left ventricular ejection fraction. The Minnesota Living with Heart Failure Questionnaire (MLHFQ), a Food and Drug Administration qualified instrument for evaluating therapeutic effectiveness, was applied through the 1-year follow-up. Cell treated (n = 109) and sham procedure (n = 140) cohorts reported improved MLHFQ scores comparable between the 2 study arms (mean treatment difference with baseline adjustment −3.2 points, P = .107). Superiority of cell treatment over sham in betterment of the MLHFQ score was demonstrated in patients with pre-existing advanced left ventricular enlargement (baseline-adjusted mean treatment difference −6.4 points, P = .009). In this highly responsive subpopulation, benefit on the MLHFQ score paralleled reduction in death and hospitalization post-cell therapy (adjusted Mann-Whitney odds 1.43, 95% CI, 1.01-2.01; P = .039). The potential of cell therapy in addressing the quality-of-life dimension of heart failure requires further evaluation for disease relief.